New hope for migraine sufferers: rimegepant study aims to cut monthly attacks
NCT ID NCT06409832
First seen Jan 22, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study looks at how well the drug rimegepant works to prevent migraines in 100 people with episodic or chronic migraine. Participants will take rimegepant and report changes in their monthly migraine days over three to twelve months. The goal is to see if the drug reduces migraine frequency and is well tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
IRCCS National Neurological Institute "C. Mondino" Foundation
RECRUITINGPavia, 27100, Italy
Contact Email: •••••@•••••
-
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
RECRUITINGFlorence, 50134, Italy
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.